Background-Unrecognized obstructive sleep apnea (OSA) is highly prevalent in obesity. Both obesity and OSA are associated with vascular endothelial inflammation and increased risk for cardiovascular diseases. We investigated directly whether the endothelial alterations that are attributed commonly to obesity are in fact related to OSA. Methods and Results-Seventy-one subjects with a body mass index ranging from normal to obese underwent attended polysomnography. To assess vascular inflammation and oxidative stress directly, we quantified the expression of nuclear factor-B and nitrotyrosine by immunofluorescence in freshly harvested venous endothelial cells. To evaluate basal endothelial nitric oxide (NO) production and activity, we quantified the expression of endothelial NO synthase (eNOS) and phosphorylated eNOS. Vascular reactivity was measured by brachial artery flow-mediated dilation. Expression of eNOS and phosphorylated eNOS and flow-mediated dilation were significantly lower, whereas expression of nitrotyrosine was significantly greater in OSA patients (nϭ38) than in OSA-free subjects (nϭ33) regardless of central adiposity. Expression of nuclear factor-B was greater in obese OSA patients than in obese OSA-free subjects (Pϭ0.004). Protein expression and flow-mediated dilation were not significantly affected by increasing body mass index or central obesity in OSA patients and in OSA-free subjects. After 4 weeks of continuous positive airway pressure therapy, flow-mediated dilation and expression of eNOS and phosphorylated eNOS significantly increased whereas expression of nitrotyrosine and nuclear factor-B significantly decreased in OSA patients who adhered to continuous positive airway pressure Ն4 hours daily. Conclusions-Untreated OSA rather than obesity is a major determinant of vascular endothelial dysfunction, inflammation, and elevated oxidative stress in obese patients.
T he prevalence of obstructive sleep apnea (OSA) increases markedly with increasing adiposity. 1 Fifty to seventy percent of overweight and obese subjects have OSA. 2 Despite such an overwhelming association, OSA remains unrecognized in the vast majority of obese subjects. 3, 4 Obesity and OSA are considered independent risk factors for cardiovascular diseases. 5, 6 Both obesity and OSA have been associated with the vascular endothelial alterations that underlie the development and progression of atherosclerosis. [7] [8] [9] [10] [11] [12] [13] Whereas obesity is regarded as a confounding factor in evaluations of vascular endothelial function in patients with OSA, the likely presence of OSA is not routinely considered in evaluations of endothelial function in obesity.
Clinical Perspective on p 1021
Considering the high prevalence of unsuspected OSA among obese subjects, the vascular endothelial alterations that are commonly attributed to obesity may, in fact, be related to OSA. Muscle sympathetic nerve activity is increased when obesity and OSA coexist, whereas it is unaffected by obesity alone. 14 Recurrent hypoxia during transient cessation of breathing in OSA may exacerbate visceral adipose tissue hypoxia and thereby promote macrophage infiltration of adipose tissue. [15] [16] [17] Whether unrecognized OSA is an important determinant of the vascular endothelial alterations commonly attributed to obesity has not been investigated. Such a possibility is therapeutically relevant, considering the challenge of weight reduction and the beneficial impact of therapy for OSA on cardiovascular risk. 18 Accordingly, the present study was undertaken to assess directly vascular endothelial function in normal-weight, overweight, and obese subjects who were systematically evaluated for OSA. We hypothesized that OSA rather than obesity is largely responsible for vascular endothelial alterations in obese subjects.
Methods

Study Sample
We prospectively recruited normal-weight (body mass index [BMI] Ͻ25 kg/m 2 ), overweight (BMI, 25 to 29.9 kg/m 2 ), and obese (BMI Ն30 kg/m 2 ) subjects from the community through advertising (nϭ40) and from the Sleep Disorders Center at Columbia University (nϭ31) between March 2006 and April 2009. None of the study participants had been evaluated for OSA before the present study. All of the study participants underwent polysomnography. An apnea-hypopnea index (AHI) Ն5 obstructive events per hour of sleep established the diagnosis of OSA. Study participants with AHI Ͻ5 events per hour were considered OSA free. Except for possible obesity, physical examination and routine laboratory tests were normal in all of the study participants. Waist circumference was defined as the minimal abdominal circumference between the lower edge of the rib cage and the iliac crest. Waist-to-hip ratio was defined as waist circumference divided by the circumference determined over the femoral heads (hip circumference). The circumferences were obtained with a flexible tape measure while maintaining close contact with skin and without compressing the underlying tissues. Subjects were in a standing position and breathing normally. Normal waist circumference was defined as Ͻ40 in for men and Ͻ35 in for women. Normal waist-to-hip ratio was defined as Յ0.90 for men and Յ0.85 for women. 19 Patients with hypertension, coronary artery disease, heart failure, a history of stroke, diabetes mellitus, chronic obstructive or restrictive pulmonary disease, chronic kidney disease, dyslipidemias, or tobacco use within the past 10 years were ineligible for the study. The study participants were not receiving medications or nutritional supplements. The Columbia University Committee on Human Research approved the study. All of the study participants gave written informed consent.
Study Protocol
All of the study participants underwent attended polysomnography as previously described. 20 Endothelial cell harvesting and flowmediated dilation (FMD) were performed between 9 and 11 AM after polysomnography while study participants were in a fasting state. All of the newly diagnosed patients with OSA underwent continuous positive airway pressure (CPAP) titration. All of the experimental procedures were repeated after a 4-week treatment period in all OSA patients.
Polysomnography and CPAP Therapy
Polysomnography and CPAP titration were performed according to the recommendations of the American Academy of Sleep Medicine. [21] [22] [23] Patients with OSA who had AHI Ն20 events per hour (nϭ19) underwent split-night polysomnography. The titration protocol for split-night titration studies was identical to that for full-night titration studies. All of the patients had a respiratory disturbance index Ͻ5 and a minimum SaO 2 Ͼ90% at the prescribed CPAP pressure. 23 (Details regarding polysomnography are available in the online-only Data Supplement.) Experimental procedures were performed 48 hours after the split-night or the full-night titration polysomnography to avoid any CPAP interference. Adherence to CPAP was defined as CPAP use Ն4 hours daily. 18 Adherence was assessed by use of a CPAP device with compliance software.
Vascular Endothelial Cell Harvesting
A 20-gauge angiocatheter was inserted into a superficial forearm vein. Under sterile conditions, 3 J-shaped vascular guidewires (Arrow, Reading, Pa) were sequentially advanced into the vein up to 10 cm. Endothelial cells were retrieved from the wire tips by washing with endothelial cell dissociation buffer. Endothelial cells were recovered by centrifugation and fixed with 3.7% formaldehyde in PBS for 10 minutes, washed twice with PBS, transferred to poly-L-lysine-coated slides (Sigma, St Louis, Mo), and air dried at 37°C. The slides were stored at Ϫ80°C until analyzed. Harvesting yielded 1365 (range, 921 to 1767) endothelial cells.
Immunofluorescence for Protein Expression
To assess vascular inflammation and oxidative stress, we measured venous endothelial expression of nuclear factor-B (NFB) and nitrotyrosine by quantitative immunofluorescence. 13 To evaluate basal endothelial nitric oxide (NO) production and activity, we measured venous endothelial expression of total NO synthase (eNOS) and activated eNOS (phosphorylated eNOS at serine 1177 [P-eNOS]).
Endothelial cells were permeabilized in PBS/0.5% Triton X-100. Nonspecific sites were blocked with PBS-5% donkey serum. Endothelial cells were incubated with monoclonal antibodies against eNOS (Becton Dickinson Transduction Laboratories, San Jose, Calif), P-eNOS, nitrotyrosine (Upstate Biotechnology, Chicago, Ill), and NFB (Santa Cruz Biotechnologies, Santa Cruz, Calif), followed by Cy3-conjugated donkey anti-mouse antibodies (Jackson ImmunoResearch Laboratories, West Grove, Pa). Appropriate negative control slides were generated with preimmune IgG. Polyclonal anti-von Willebrand factor antibodies (DAKO, Glostrup, Denmark) were then used, followed by FITC-conjugated secondary antibodies. Nuclei were stained with DAPI (Molecular Probes, Carlsbad, Calif). Between-experiment variability was standardized through the use of reference slides of human umbilical venous endothelial cells obtained from the same culture dish. Slides from study participants were stained concurrently with 1 slide of human umbilical venous endothelial cells. Endothelial cells were analyzed with a fluorescent microscope under identical conditions (Nikon Eclipse E600, Melville, NY) and were captured by digital camera (Q Imaging Retiga EXi, Surrey, British Columbia, Canada). The reader was blinded to the subject's identity. Nuclear and von Willebrand factor staining identified endothelial cells. Slides were systematically read left to right and top to bottom. Twenty-five consecutive endothelial cells were analyzed from each slide. The number of positive (bright) intracellular pixels was quantified with commercially available software (Adobe Photoshop 7.0) and normalized to reference human umbilical venous endothelial cell slides to calculate pixel ratios (arbitrary units). Quantification by immunofluorescence has been validated repeatedly against immunoblotting in venous endothelial cells with coefficient correlations of 0.99 and 0.97. 9, 24 Reproducibility of quantitative immunofluorescence of protein expression in venous endothelial cells harvested on the same day was previously assessed. 24 The overall coefficient of variation and the mean measurement error for protein expression in venous endothelial cells (17 duplicate measurements) were 11% and 286 pixels, respectively. Reproducibility over time was assessed in 10 healthy OSA-free subjects. The overall coefficient of variation in protein expression was 8% and the mean measurement error was 267 pixels in cells harvested 4 weeks apart from the same site.
Brachial Artery FMD
Vascular reactivity of the brachial artery was measured in the arm contralateral to the endothelial harvesting site by FMD according to the guidelines of the International Brachial Artery Reactivity Task Force. 25 Details regarding FMD are available in the online-only Data Supplement.
Statistical Analysis
Continuous data are presented as meanϮSD and median (quartiles 1 to 3) and compared by use of Wilcoxon rank-sum tests. Categorical data are presented as frequency and percentage and compared by use of 2 tests. Two-way ANOVA that included BMI category, the diagnosis of OSA, and multiplicative interaction terms for BMI category and the diagnosis of OSA as fixed effects was used to examine the independent associations between these factors and the expression of eNOS, P-eNOS, nitrotyrosine, and NFB and FMD. Waist circumference and waist-to-hip ratio categories were examined in a fashion similar to BMI category. The Tukey multiple-comparison procedure was used to control the type I error rate. Spearman correlation coefficient was used to examine unadjusted associations between BMI, waist circumference, and waist-to-hip ratio and protein expression and FMD in OSA patients and OSA-free subjects. Generalized additive models with loess smoothing functions for continuous variables were used to examine the linear relationship between severity of OSA (as assessed by AHI, nadir SaO 2 , and time spent below an SaO 2 of 90% during sleep [tϽSaO 2 90%]) and protein expression and FMD with adjustment for age, gender, and BMI. Linear mixed-effects models with CPAP adherence, age, gender, BMI, time (baseline or followup), and an interaction term for CPAP adherence and time as fixed effects and subjects as random effects were used to examine the change in protein expression and FMD in OSA patients from baseline to follow-up. Statistical significance was defined as 2-tailed values of PϽ0.05. Statistical analysis was performed with SAS 9.1 (SAS Institute, Cary, NC) and the gam function in R 2.8.1 (R Foundation, Vienna, Austria).
Results
Seventy-one subjects were studied. Thirty-eight subjects were found to have OSA, and 33 subjects were free of OSA. The clinical and laboratory characteristics of the study subjects are presented in the Table. Age, gender, BMI, blood pressure, fasting blood glucose, and total cholesterol level were similar in OSA patients and OSA-free subjects. Waist circumference and waist-to-hip ratio tended to be greater in OSA patients than in OSA-free subjects. Patients with OSA had significantly lower SaO 2 nadir during sleep and had more daytime sleepiness as measured by the Epworth Sleepiness Scale than OSA-free subjects.
Endothelial Protein Expression in Patients With OSA and OSA-Free Subjects
Expression of eNOS and P-eNOS (markers of endothelial NO production and activity) was significantly lower whereas expression of nitrotyrosine (a marker of oxidative stress) was significantly greater in OSA patients than in OSA-free subjects regardless of central adiposity (Figure 1) . Expression of eNOS and P-eNOS was significantly lower whereas expression of NFB (a marker of inflammation) was significantly greater in obese OSA patients than in obese OSA-free subjects. Expression of NFB was also significantly greater in OSA patients with increased waist circumference and waist-to-hip ratio than in their OSA-free counterparts ( Figure  1 ). Neither BMI nor central obesity (increased waist circumference or waist-to-hip ratio) significantly altered protein expression in OSA patients and OSA-free subjects (Figure 1) . The effects of obesity on endothelial protein expression were also analyzed with BMI, waist circumference, and waist-tohip ratio expressed as continuous variables. Endothelial protein expression did not significantly correlate with BMI, waist circumference, and waist-to-hip ratio in OSA patients and OSA-free subjects ( Figure I of the online-only Data Supplement). Expression of eNOS, P-eNOS, nitrotyrosine, and NFB was similar in obese (BMI Ն30 kg/m 2 ) and nonobese (BMI Ͻ30 kg/m 2 ) study participants when not stratified by the presence of OSA (PϾ0.20 for all).
Flow-Mediated Dilation
Brachial artery FMD, an indirect marker of endothelial NO-mediated reactivity, was significantly lower in normal-weight OSA patients than in OSA-free subjects of similar weight. Overweight OSA patients tended to have lower FMD than overweight OSA-free subjects (Figure 2 ). Patients with OSA and normal or increased waist circumference and normal waist-to-hip ratio had lower FMD than their OSA-free counterparts (Figure 2 ). Resting brachial diameter and percent reactive hyperemia after arm cuff deflation were similar in OSA patients and OSA-free subjects. BMI, waist circumference, and waist-to-hip ratio did not significantly alter FMD in OSA patients and OSA-free subjects (Figure 2 ). Brachial artery FMD did not significantly correlate with BMI, waist circumference, and waist-to-hip ratio in OSA patients and OSA-free subjects ( Figure II of the online-only Data Supplement).
Endothelial Function and OSA Severity
Endothelial expression of eNOS and P-eNOS correlated inversely with AHI, whereas expression of NFB and nitrotyrosine correlated directly with AHI after adjustment for age, gender, and adiposity ( Figure 3 ). Similar correlations were noted between baseline protein expression and tϽSaO 2 90% and SaO 2 nadir (PϽ0.001 for all).
Effects of CPAP Therapy on Endothelial Protein Expression
Twenty-six patients with OSA tolerated CPAP for 4 weeks, and 12 did not because of discomfort. Adherence to CPAP ranged from 1 to 8 hours. Nineteen patients adhered to CPAP Ն4 hours daily for an average of 6.0Ϯ1.4 hours. The 7 remaining patients adhered to CPAP Ͻ4 hours daily (average, 2.1Ϯ0.4 hours). Adherence to CPAP therapy was similar in patients who underwent split-night and full-night diagnostic polysomnography. Age, severity of obesity and OSA, daytime sleepiness, blood pressure, fasting glucose, and total cholesterol levels, as well as baseline endothelial protein expression and FMD, were similar in patients who tolerated and did not tolerate CPAP. Body weight and blood pressure remained unchanged during CPAP therapy. Endothelial expression of eNOS and P-eNOS increased whereas expression of NFB and nitrotyrosine decreased in patients who adhered to CPAP Ն4 hours daily after adjustment for age, gender, and BMI (Figure 4) . Similarly, FMD increased in patients who adhered to CPAP Ն4 hours daily (Pϭ0.02). When patients adhered to CPAP Ն4 hours daily, FMD and expression of eNOS and NFB were no longer different from that of OSA-free subjects (P ϭ0.08 to 0.63). Expression of P-eNOS remained lower and expression of nitrotyrosine remained greater than in OSA-free subjects despite adherence to CPAP Ն4 hours daily (Pϭ0.005 and 0.001, respectively). Endothelial protein expression and FMD did not change in patients who used CPAP Ͻ4 hours daily or declined CPAP (Pϭ0.10 to 0.72).
Discussion
The present findings indicate that OSA rather than obesity is a major determinant of endothelial dysfunction, inflammation, and elevated oxidative stress in obese patients. Increased body weight and central obesity were not associated with vascular endothelial dysfunction, inflammation, and elevated oxidative stress in the absence of OSA. Furthermore, increasing adiposity does not appear to exacerbate the effects of OSA on the vascular endothelium.
A quarter of the American adult population suffers from OSA that remains overwhelmingly unrecognized. 1,3,4 Moreover, only half of the patients diagnosed with OSA receive Figure 1 . Expression of eNOS, P-eNOS, nitrotyrosine, and NFB in venous endothelial cells obtained from patients with OSA and OSA-free subjects. Patients with OSA (nϭ38; red boxes) and OSA-free subjects (nϭ33; white boxes) were stratified as being normal weight (N), overweight (OV), or obese (OB) by BMI and as having central obesity by increased (I) vs normal (N) waist circumference or waist-to-hip ratio. Expression of eNOS and P-eNOS was lower, whereas expression of nitrotyrosine was greater in OSA patients vs OSA-free subjects for all central adiposity categories. Expression of eNOS and P-eNOS was lower in obese OSA patients than in obese OSA-free subjects. Expression of NFB was significantly greater in OSA patients who were obese or had central obesity than in their OSA-free counterparts. Expression of eNOS, P-eNOS, nitrotyrosine, and NFB was similar within all adiposity categories in OSA patients and in OSA-free subjects (PϭNS for all). Data are shown as box plots with median values and quartiles 1 to 3 represented by horizontal black lines and the upper and lower bounds of the box, respectively. Whisker tips extend to the most extreme value within 1.5 times quartiles 1 to 3. Outliers are not shown. au indicates arbitrary units.
treatment. 4 The prevalence of unrecognized OSA increases markedly with increasing adiposity. When adiposity increases by 1 SD, the risk of unrecognized sleep-disordered breathing increases by 3-fold. 1 Pervasive underdiagnosis of OSA may be due to the lack of daytime symptoms such as excessive sleepiness in the vast majority of OSA patients. 1 A thorough history and physical examination cannot reliably exclude the presence of OSA even in severely obese patients. 26 Regardless of the presence of daytime symptoms, OSA is an independent risk factor for cardiovascular diseases and increased mortality. 5, 27 Patients with OSA experience repetitive episodes of hypoxia/reoxygenation during transient cessation of breathing that reduce NO availability and promote inflammation and oxidative stress. [11] [12] [13] 28, 29 Endothelial alterations similar to that of OSA have been reported in apparently healthy obese subjects. 9 Cross-sectional studies suggest that endotheliumdependent arterial dilation, as assessed by FMD or direct intraarterial administration of acetylcholine, is reduced in obesity. 7, 30 Moreover, BMI and visceral obesity correlate inversely with endothelium-dependent vasodilation in apparently healthy subjects. 30 -32 Elevated levels of soluble intracellular and vascular adhesion molecule-1 and E-selectin in obesity are consistent with endothelial inflammation and activation. [33] [34] [35] Increased systemic oxidative stress is thought to contribute to endothelial dysfunction in obesity. 36 -39 Central distribution of adiposity, a major determinant of endothelial dysfunction, inflammation, and increased oxidative stress, is strongly associated with OSA. 2, 33, 36, 39 Because the majority of obese subjects suffer from unrecognized OSA, it is likely that OSA was present in a substantial subset of apparently healthy obese subjects who participated in the studies that linked obesity to endothelial dysfunction and cardiovascular disease.
Direct evidence that obesity is associated with endothelial inflammation and increased vascular oxidative stress was recently reported. 9, 40 Venous endothelial expression of NFB and nitrotyrosine was found to be greater in apparently healthy overweight and obese subjects than in their normalweight counterparts. 9 However, as in the above studies, the presence of unsuspected OSA was not systematically excluded. In contrast to previous studies that directly and indirectly supported an association between obesity and endothelial dysfunction and inflammation, we could not link central obesity to vascular endothelial dysfunction, inflammation, and increased oxidative stress in the absence of OSA. Although various factors may have contributed to these discrepant findings, the systematic exclusion of coexistent OSA clearly differentiates the present study from others.
Our findings of OSA-related vascular endothelial dysfunction in otherwise healthy obese patients concur with previous reports. 11, 12 Compared with healthy subjects matched for adiposity, endothelium-dependent vasodilation is impaired in patients with OSA and improves after treatment. Our findings are also concordant with the observation that muscle sympathetic nerve activity is increased in obese patients with OSA but not in patients with obesity alone. 14 Increased endothelial expression of eNOS and P-eNOS and decreased expression of nitrotyrosine and NFB after effective CPAP therapy provide further evidence that OSA rather than obesity was predominantly responsible for endothelial alterations in our study sample. Patients with OSA exhibited endothelial alterations Relationship between brachial artery FMD and adiposity. Brachial artery FMD was lower in patients with OSA (red boxes) who were normal weight compared with OSA-free subjects (white boxes) with similar body habitus measurements. A nonsignificant trend toward lower FMD was observed in overweight OSA patients vs overweight OSA-free subjects. Brachial artery FMD was lower in patients with OSA who had normal (N) or increased (I) waist circumference and normal waist-to-hip ratio vs OSA-free subjects with similar adiposity. Brachial artery FMD was similar in OSA-free subjects who were normal weight (N), overweight (OV), and obese (OB) and/or had normal or increased waist circumference and waist-to-hip ratio (PϭNS for all). Brachial artery FMD was also similar in OSA patients who were normal weight, overweight, and obese and/or had normal or increased waist circumference and waist-to-hip ratio (PϭNS for all). Data are shown as box plots with median values and quartiles 1 to 3 represented by horizontal black lines and the upper and lower bounds of the box, respectively. Whisker tips extend to the most extreme value within 1.5 times quartiles 1 to 3.
that were reversible with CPAP regardless of the severity of adiposity. Although CPAP was not allocated randomly to our patients, reversal of endothelial dysfunction and inflammation in the absence of change in body weight strongly suggests that OSA is largely responsible for these endothelial alterations in obesity. The observed correlation between severity of OSA and the extent of endothelial alterations further supports OSA as a major contributor to endothelial dysfunction, inflammation, and oxidative stress in obese patients. Relationship between expression of eNOS, P-eNOS, nitrotyrosine, and NFB and the severity of OSA assessed by the AHI after adjustment for age, gender, and BMI. Expression of eNOS and P-eNOS correlated inversely with AHI, whereas expression of nitrotyrosine and NFB correlated directly with AHI. P values reflect the linear associations between protein expression and AHI using generalized additive models with loess smoothers for continuous variables. Although adipose tissue is a well-known source of inflammation, the mechanisms that trigger and maintain the inflammatory response in obesity are incompletely understood. Adipose tissue hypoxia has recently been proposed as one of the major triggers of macrophage infiltration in adipose tissue. [15] [16] [17] However, the cascade of events that lead to adipose tissue hypoxia remains unclear. 15 The cyclic hypoxia associated with cessation of breathing in OSA may promote adipose tissue hypoxia and inflammation in obesity.
The precise mechanisms underlying cardiovascular risk in OSA and obesity cannot be ascertained from the study of the venous endothelium. Local biomechanical forces that affect arterial endothelial cells at specific sites play an essential role in determining regional susceptibility to atherosclerosis. [41] [42] [43] [44] Thus, endothelial biopsy at specific sites of the arterial vasculature will likely be required to determine the precise mechanisms underlying atherosclerosis in OSA and obesity. Endothelial cells undergo significant phenotypic drift when removed from their native environment and cultured in vitro. 41 Direct characterization of harvested venous endothelial cells without the artifact of culture conditions provides novel insight into the mechanisms that mediate the vascular response to systemic inflammation in OSA and obesity.
Conclusions
OSA rather than obesity appears to be predominantly responsible for vascular endothelial dysfunction, inflammation, and increased oxidative stress in obese patients. Accurate assessment of obesity-related vascular risk requires systematic exclusion of unsuspected OSA. Reversal of vascular inflammation with effective therapy for OSA emphasizes the importance of vigilant search and prompt treatment of OSA in overweight and obese subjects.
